m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02799)
Name
Piceatannol
Synonyms
piceatannol; 10083-24-6; 3-Hydroxyresveratol; piceatanol; astringinin; 3,5,3',4'-Tetrahydroxystilbene; (E)-4-(3,5-dihydroxystyryl)benzene-1,2-diol; 3,3',4'5-Tetrahydroxystilbene; 4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,2-diol; 3,3',4,5'-Tetrahydroxystilbene; UNII-6KS3LS0D4F; NSC 365798; NSC-365798; NSC 622471; 6KS3LS0D4F; CHEMBL69863; 3,3',4,5'-Stilbenetetrol; 4-[(E)-2-(3,5-dihydroxyphenyl)vinyl]benzene-1,2-diol; 4339-71-3; CHEBI:28814; C14H12O4; NSC365798; NSC622471; 1,2-Benzenediol, 4-(2-(3,5-dihydroxyphenyl)ethenyl)-
    Click to Show/Hide
Status
Investigative
Structure
Formula
C14H12O4
InChI
1S/C14H12O4/c15-11-5-10(6-12(16)8-11)2-1-9-3-4-13(17)14(18)7-9/h1-8,15-18H/b2-1+
InChIKey
CDRPUGZCRXZLFL-OWOJBTEDSA-N
PubChem CID
667639
TTD Drug ID
D0O0VZ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Interferon regulatory factor 3 (IRF3)
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Interferon regulatory factor 3 (IRF3) is a therapeutic target for Piceatannol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Piceatannol through regulating the expression of Interferon regulatory factor 3 (IRF3). [1], [2]
References
Ref 1 N6-Methyladenosine Modification Controls Circular RNA Immunity. Mol Cell. 2019 Oct 3;76(1):96-109.e9. doi: 10.1016/j.molcel.2019.07.016. Epub 2019 Aug 29.
Ref 2 PARP inhibitors as antitumor agents: a patent update (2013-2015). Expert Opin Ther Pat. 2017 Mar;27(3):363-382. doi: 10.1080/13543776.2017.1259413. Epub 2016 Nov 21.